DelveInsight’s, “Acute Ischemic Stroke Pipeline Insight 2024” report provides comprehensive insights about 20+ companies and 25+ pipeline drugs in Acute Ischemic Stroke pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Acute Ischemic Stroke Research. Learn more about our innovative pipeline today! @ Acute Ischemic Stroke Pipeline Outlook
Key Takeaways from the Acute Ischemic Stroke Pipeline Report
- In November 2024:- Shanghai Hutchison Pharmaceuticals Limited- This study is a Phase II, multicenter, randomized, double Blind, placebo-Controlled design. Participants receive twice daily dosing for 7 consecutive days, or once on Days 1 and Day 8 and twice daily on Days 2 to Day 7, with each subject scheduled to receive 14 doses throughout the clinical trial. 270 Participants will be randomized 1:1:1 to SHPL-49 injection treated group (3 ampoules of SHPL-49 injections, BID), SHPL-49 injection treated group (6 ampoules of SHPL-49 injections , BID) and placebo group (BID).
- DelveInsight’s Acute Ischemic Stroke pipeline report depicts a robust space with 180+ active players working to develop 200+ pipeline therapies for Acute Ischemic Stroke treatment.
- The leading Acute Ischemic Stroke Companies such as Tasly Pharmaceutical, Revalesio Corporation, Avilex Pharma, GNT Pharma, Biogen, AptaTargets, NC Medical Research, Prolong Pharmaceuticals, Saillant Therapeutics, TargED Biopharmaceuticals and others.
- Promising Acute Ischemic Stroke therapies such as Sovateltide, Tenecteplase, BB-031, hUCB, LT3001, Elezanumab, Redasemtide, Cerebrolysin, SP-8203, and others.
Stay informed about the cutting-edge advancements in Acute Ischemic Stroke treatments. Download for updates and be a part of the revolution in care @ Acute Ischemic Stroke Clinical Trials Assessment
Acute Ischemic Stroke Emerging Drugs Profile
- Prourokinase recombinant: Tasly Pharmaceutical
Prourokinase recombinant, is an investigational drug being developed by Tasly Pharmaceutical for the treatment of Acute Ischemic Stroke. Recombinant human (rh) Pro-UK, is a novel type of thrombolytic, which preferentially activates plasminogen on the fibrin surface and induces fibrin-selective clot lysis. It has the advantages of more potent efficacy and less adverse reactions in comparison with other thrombolytics. Advantages of thrombolytic therapy using rhPro-UK for patients with acute myocardial infarction include its reliable curative effect and high safety. Currently, the drug is in the Phase III stage of its development for the treatment of Acute Ischemic Stroke.
- RNS60: Revalesio Corporation
RNS60 is being developed to provide disease modifying and potentially restorative treatments for neurological diseases. It activates intracellular signaling pathways to increase mitochondrial biogenesis and function and reduce inflammation. RNS60 safely protects neurons and oligodendrocytes and modulates the activity of immune cells to restore homeostasis. RNS60 has been granted Orphan Drug and Fast Track designations for ALS from the U.S. Food and Drug Administration. Currently, the drug is in the Phase II stage of its development for the treatment of Acute Ischemic Stroke.
- AVLX 144: Avilex Pharma
AVLX-144 is a dimeric peptide-like drug candidate for the treatment of AIS, which targets the intracellular scaffolding protein, PSD-95. AVLX-144 is an extensively optimized dimeric PSD-95 inhibitor and a clinical lead candidate for the treatment of acute conditions such as AIS and subarachnoid hemorrhage (SAH). PSD-95 bridges the glutamate receptor subtype - the N-methyl-D-aspartate (NMDA) receptor and neuronal nitric oxide synthase (nNOS) via its two PDZ domains and AVLX-144 binds to both these PDZ domains simultaneously. The specific design of AVLX-144 provides several key advantages such as exceptionally high affinity to PSD-95, increased stability, and enhanced neuroprotective properties. Currently, the drug is in the Phase I stage of its development for the treatment of Acute Ischemic Stroke.
Learn more about Acute Ischemic Stroke Drugs opportunities in our groundbreaking Acute Ischemic Stroke Research and development projects @ Acute Ischemic Stroke Unmet Needs
Acute Ischemic Stroke Companies
Tasly Pharmaceutical, Revalesio Corporation, Avilex Pharma, GNT Pharma, Biogen, AptaTargets, NC Medical Research, Prolong Pharmaceuticals, Saillant Therapeutics, TargED Biopharmaceuticals and others
Acute Ischemic Stroke pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Acute Ischemic Stroke Products have been categorized under various ROAs such as
- Intravenous
- Subcutaneous
- Oral
- Intramuscular
Acute Ischemic Stroke Products have been categorized under various Molecule types such as
- Monoclonal antibody
- Small molecule
- Peptide
Discover the latest advancements in Acute Ischemic Stroke treatment by visiting our website. Stay informed about how we're transforming the future of disease @ Acute Ischemic Stroke Market Drivers and Barriers, and Future Perspectives
Scope of the Acute Ischemic Stroke Pipeline Report
- Coverage- Global
- Acute Ischemic Stroke Companies such as Tasly Pharmaceutical, Revalesio Corporation, Avilex Pharma, GNT Pharma, Biogen, AptaTargets, NC Medical Research, Prolong Pharmaceuticals, Saillant Therapeutics, TargED Biopharmaceuticals and others.
- Acute Ischemic Stroke Therapies- Sovateltide, Tenecteplase, BB-031, hUCB, LT3001, Elezanumab, Redasemtide, Cerebrolysin, SP-8203, and others.
- Acute Ischemic Stroke Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Acute Ischemic Stroke Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of Acute Ischemic Stroke Pipeline on our website @ Acute Ischemic Stroke Emerging Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- Acute Ischemic Stroke: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Acute Ischemic Stroke– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Enzastaurin: Denovo BioPharma
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- MDNA55: Medicenna Therapeutics, Inc.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- Zotiraciclib: Adastra Pharmaceuticals
- Drug profiles in the detailed report…..
- Preclinical and Discovery Stage Products
- RGN6024: Reglagene, Inc.
- Drug profiles in the detailed report…..
- Inactive Products
- Acute Ischemic Stroke Key Companies
- Acute Ischemic Stroke Key Products
- Acute Ischemic Stroke- Unmet Needs
- Acute Ischemic Stroke- Market Drivers and Barriers
- Acute Ischemic Stroke- Future Perspectives and Conclusion
- Acute Ischemic Stroke Analyst Views
- Acute Ischemic Stroke Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/